Dr Chris Lord

Tackling cancer’s resistance to treatment

Dr Chris Lord is based at The Institute of Cancer Research, London. He is investigating why some cancers can become resistant to treatment with drugs called PARP inhibitors.

PARP inhibitors are used to treat certain types of breast and ovarian cancers and have a high success rate. They work by preventing cancer cells from fixing fatal faults in their DNA.

But cancers can stop responding to treatment with PARP inhibitors. Dr Lord is exploring the genetic changes in the cancer cells that can cause this resistance to happen.

By understanding this, Dr Lord hopes to find a way to predict whether resistance will happen. This could suggest ways to delay or even stop it, for example by combining other drugs with PARP inhibitors.

Cancer biology

The Institute of Cancer Research, London

Email: chris.lord@icr.ac.uk